Vanda Pharmaceuticals
VNDA
190 hedge funds and large institutions have $389M invested in Vanda Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 76 increasing their positions, 52 reducing their positions, and 16 closing their positions.
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
46% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 52
7% more funds holding
Funds holding: 178 → 190 (+12)
0.54% more ownership
Funds ownership: 97.51% → 98.05% (+0.54%)
16% less call options, than puts
Call options by funds: $354K | Put options by funds: $420K
29% less capital invested
Capital invested by funds: $544M → $389M (-$155M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$15.9M |
| 2 |
BlackRock
New York
|
+$5.16M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.49M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$3.17M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$15.6M |
| 2 |
EIP
Epoch Investment Partners
New York
|
-$12.9M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$10.5M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.93M |
| 5 |
Renaissance Technologies
New York
|
-$3.95M |
VNDA Hedge Fund Activity: Q4 2022 in Review
190 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2022, worth a combined $389M — down 29% from $544M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new VNDA positions and 16 closed out — a net gain of 13 holders — while 76 added to existing stakes and 52 trimmed.
The largest buyer was Millennium Management, adding an estimated $15.9M. The largest seller was Macquarie Group, cutting an estimated $15.6M.
- 190 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2022, up from 178 in Q3 2022.
- Funds reported $389M of Vanda Pharmaceuticals stock for Q4 2022, down 29% quarter-over-quarter.
- 29 funds opened new Vanda Pharmaceuticals positions in Q4 2022 and 16 closed out, a net change of +13 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $15.9M added.
- The largest Vanda Pharmaceuticals seller in Q4 2022 was Macquarie Group, an estimated $15.6M sold.
Based on aggregated 13F filings for Q4 2022.